MP-1000
- Generic Name
- MP-1000
Robust Pipeline of 80+ Therapies Advancing in Psoriasis Treatment Landscape
• DelveInsight's 2025 Psoriasis Pipeline Report reveals over 80 companies developing 80+ pipeline therapies, highlighting significant R&D investment in this therapeutic area.
• Promising treatments in development include topical roflumilast (Arcutis Biotherapeutics) in Phase III trials and GSK2982772 (GlaxoSmithKline), a novel RIPK1 inhibitor in Phase I development.
• Alumis Inc. has initiated a long-term extension study for ESK-001 in moderate to severe plaque psoriasis patients, evaluating safety, efficacy, and durability of response over 24 weeks.
Novavax Launches Clinical Trial for JN.1 Subvariant COVID-19 Vaccine
Novavax initiates a new clinical trial to evaluate the safety and immunogenicity of its JN.1 subvariant vaccine (NVX CoV2705) with Matrix-M adjuvant. The study will compare results with the previously authorized NVX-CoV2601 vaccine, marking a significant step in addressing emerging COVID-19 variants.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath